CD47 and neoplasm: Another IAP inhibitor, LCL161, modulates the tumor microenvironment of multiple myeloma and induces strong immune activation, thereby stimulating anti-tumor phagocytic activity and durable anti-tumor immunity; when combined with LCL161 and PD-1 antibody, it significantly enhances anti-PD-1 antibody efficacy.157